Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$85.39 USD
+0.11 (0.13%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $85.45 +0.06 (0.07%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Revvity Inc. has a PEG ratio of 2.28 compared to the Medical Services industry's PEG ratio of 1.49.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RVTY 85.39 +0.11(0.13%)
Will RVTY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RVTY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVTY
RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View
Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
RVTY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates
Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
Other News for RVTY
RVTY's price rises by 1.52% on September 16, though its technical setup remains stable.
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Eli Lilly & Co (LLY) and Revvity (RVTY)
RVTY rises 1.36% on September 15, leaving the technical picture intact
KeyBanc Reaffirms Their Buy Rating on Revvity (RVTY)
Is RVTY positioned for a breakdown? 180 Bearish Setup shows up after declining 3.28%